Skip to main content

Advertisement

SpringerLink
Log in

Earlier eligibility for ART good value for money

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. defined as incremental cost-effectiveness ratio below the country's per-head GDP

References

  1. Eaton JW, et al. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. The Lancet Global Health : 10 Dec 2013. Available from: URL: http://dx.doi.org/10.1016/S2214-109X(13)70172-4.

    Google Scholar 

  2. Dabis F. Test and treat all as soon as possible The Lancet Global Health : 10 Dec 2013. Available from: URL: http://dx.doi.org/10.1016/S2214-109X(13)70178-5.

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Earlier eligibility for ART good value for money. PharmacoEcon Outcomes News 694, 5 (2014). https://doi.org/10.1007/s40274-014-0965-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-0965-1

Search

Navigation